

Atezolizumab IPSOS

PRELIMINARY SCORE


CURATIVE


NON-CURATIVE

OS

ADJUSTMENTS


Quality of life







No QoL benefit


Serious and disabling adverse effects





Other adjustments





Atezolizumab IPSOS

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

4

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Atezolizumab as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy

Experimental Arm: Atezolizumab

Control Arm: Vinorelbine or gemcitabine (by investigator choice )



